Breaking News

Biogen, Samsung Bioepis Enter New Biosimilars Transaction

Secures exclusive rights to commercialize ophthalmology biosimilars referencing Lucentis and Eylea

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Inc. has entered a new transaction with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis and SB15 referencing Eylea, in major markets worldwide. Biogen will also acquire exclusive commercialization rights for its anti-TNF portfolio, including BENEPALI (etanercept), FLIXABI (infliximab) and IMRALDI (adalimumab), in China. Biogen will acquire an option to extend its existing commercial agreement with Samsu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters